Sector Update: Healthcare Shares Flat; Agenus up 10% on Malaria Vaccine Data

By
A A A

Healthcare stocks:

JNJ: flat

PFE: flat

ABT: flat

MRK: flat

AMGN: flat

Healthcare shares are flat in pre-market, while Agenus Inc. ( AGEN ) shares are up more than 10% pre-market after data from a Phase 3 trial showed GlaxoSmithKline's ( GSK ) malaria vaccine, which contains Agenus' QS-21 Stimulon adjuvant, protected children against malaria for 18 months after the injection.

GSK is flat at $50.13.

The RTS,S is the most advanced malaria vaccine candidate in the world and the first vaccine candidate to show in clinical trials that it can help protect young children and infants living in malaria-endemic areas against clinical disease and infection caused by Plasmodium falciparum.

And, Sucampo Pharmaceuticals ( SCMP ) said results from a study of its lubiprostone constipation drug showed the treatment is effective and well tolerated in children and adolescents with functional constipation.

The results were published in the Journal of Pediatric Gastroenterology & Nutrition. SCMP is flat at $6.38.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


This article appears in: Investing , Commodities

Referenced Stocks: AGEN , GSK , SCMP

MT Newswires

MT Newswires

More from MT Newswires:

Related Videos

Stocks

Referenced

Most Active by Volume

85,467,945
  • $16.74 ▼ 0.30%
83,530,302
  • $12.49 ▲ 85.31%
68,697,805
  • $42.55 ▼ 0.77%
58,516,965
  • $101.63 ▼ 0.03%
49,234,469
  • $74.58 ▼ 3.74%
39,038,134
  • $8.56 ▲ 2.27%
37,813,410
  • $49.38 ▼ 5.24%
37,004,144
  • $46.24 ▼ 0.97%
As of 9/15/2014, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com